Prime Medicine, Inc.
primemedicine.comPrime Medicine Inc (NASDAQ: PRME) is a biotechnology company developing one-time curative genetic therapies based on its Prime Editing technology platform. The company has no product revenue as of its 10-K filed March 3, 2026, and finances operations through equity offerings, debt financings, and collaboration agreements. Under its Beam Collaboration Agreement, Prime Medicine licenses exclusive worldwide rights to certain Prime Editing know-how and patent rights to Beam Therapeutics for use within a defined field limited to transition point mutations in human disease treatment. The company operates from facilities in Massachusetts. Allan Reine, M.D., serves as Principal Executive Officer and Principal Financial Officer as of March 3, 2026. Cash needs are met through capital markets activity and licensing arrangements, as no commercial products have reached market.
Products & Services
Prime Medicine's core platform is Prime Editing technology, a gene editing approach designed to make precise changes to DNA. The company describes its goal as delivering one-time curative genetic therapies across a wide spectrum of diseases. No products have received regulatory approval or been commercialized as of the filing date.
Revenue Model
Prime Medicine generates no product revenue as of the 10-K filed March 3, 2026. The company funds operations through equity and convertible debt offerings, and through collaboration and licensing arrangements, including the Beam Collaboration Agreement under which it licenses Prime Editing know-how and patent rights.
Customers & Markets
Prime Medicine's end market is human disease treatment, with product candidates targeting genetic diseases. As of the 10-K filed March 3, 2026, the company has no commercial customers. Beam Therapeutics is an identified collaboration partner under the Beam Collaboration Agreement.
Geographic Exposure
Prime Medicine's facilities are located in Massachusetts, as disclosed in the 10-K filed March 3, 2026. The Beam Collaboration Agreement grants worldwide licensing rights.
Financial Snapshot
Loading...
